Trending...
- City of Tacoma Offers In-Person Workshop for Local Businesses on the Revolving Loan Fund Process
- City Council Confirms Appointment of Patti Jackson as Tacoma's Police Chief
- Council Votes on Pathways to Eviction Prevention for Spokane
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.
"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."
More on Washingtoner
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.
More on Washingtoner
Contacts
For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com
For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."
More on Washingtoner
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Achieves BPA Certification, Advancing Safe and Sustainable Digital Printing
- Joan Nissen promoted to Century Fasteners Corp. – General Manager, Aerospace & Government Sales
- Northwest Modern Fabrication Expands Manufacturing Capacity With 4,800 Sq. Ft. Addition
- NRE-HEALTH Radio Launches With a New Approach to Health Broadcasting
- City of Spokane Proposes Directing Funding to Support Families Impacted by Civil Immigration Enforcement
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.
More on Washingtoner
- From Coffee to Commutes: sMiles App Now Pays Bitcoin for Every Gift Card Purchase
- Finland's Health Authority Launches '2-4-2' Gambling Risk Limits Ahead of Expected Advertising Boom
- Evluma Launches RoadMax Edge Streetlight Series, Advancing Urban Illumination and Energy Efficiency
- Dr. Billy B. Laun II Addresses Over 120 Dental Professionals at Annual Dental Meeting
- CCHR: Taxpayer Billions Wasted on Mental Health Research as Outcomes Deteriorate
Contacts
For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com
For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
0 Comments
Latest on Washingtoner
- NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
- When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age
- Half of Finnish Online Gambling Expenditure Now Flows to Offshore Instant Casinos as License Applications Open March 1, 2026
- RTC Communications Completes Next Level Connect Fiber Expansion Bringing Multi-Gig Broadband to West Boggs Community
- EPP Pricing Platform announces leadership transition to support long-term growth and continuity
- Stolen Hearts: Reclaiming Your Child From Parental Alienation (narcissistic abuse)
- Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
- City of Tacoma Offers In-Person Workshop for Local Businesses on the Revolving Loan Fund Process
- Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount
- Aries Industries Streamlines Sewer Inspection Process With Introduction of the LETS Sidewinder
- Chronic Boss Awards Scholarships to Student Founders Living with Chronic Conditions
- Nest Finders Property Management Named #1 in Jacksonville and Ranked #99 Nationwide
- City Council Confirms Appointment of Patti Jackson as Tacoma's Police Chief
- Nashville International Chopin Piano Competition Launches First Amateur Edition
- Council Votes on Pathways to Eviction Prevention for Spokane
- Market Value Enhancement From 2 Important New US Patents Issued for Strengthening Hair Enzyme Booster Technology to Caring Brands (NAS DAQ: CABR)
- Dr. Billy Laun Will Be Attending An Advanced Airway Management Course by AIME
- HELM Audio™ Partners with PQCrypto to Future-Proof Children's Hearing and Safety Data Using Post-Quantum Cryptography
- Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4
- Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living